Land: Armenien
Sprog: engelsk
Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
pink tablet-drospirenone, ethinyl estradiol, levomefolate (levomefolate calcium); light orange tablet-levomefolate (levomefolate calcium)
Bayer Weimar GmbH & Co. KG
pink tablet-drospirenone, ethinyl estradiol, levomefolate (levomefolate calcium); light orange tablet-levomefolate (levomefolate
pink tablet-3mg+0,02mg+0,451mg
tablets film-coated
Prescription
1 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 ORAL CONTRACEPTIVE Yaz Plus ® is indicated for use by women topreventpregnancy. 1.2 PREMENSTRUAL DYSPHORIC DISORDER (PMDD) Yaz Plusis also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who chooseto use an oral contraceptive as their method of contraception. The effectiveness ofYaz Plusfor PMDD when used for morethan three menstrual cycles has not been evaluated. The essential features of PMDD according to the Diagnostic and Statistical Manual-4th edition (DSM-IV) includemarkedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features includedecreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out ofcontrol. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloatingand weight gain. In this disorder, these symptoms occur regularly during the luteal phase and remit within a few daysfollowing onset of menses;the disturbance markedly interferes with work or school, or with usual social activities andrelationships with others. Diagnosis is made by healthcare providers according to DSM-IVcriteria, with symptomatologyassessed prospectively over at least two menstrual cycles. In making the diagnosis, care should be taken to rule out othercyclical mood disorders. Yaz Plushas not been evaluated for the treatment of premenstrual syndrome (PMS). 1.3 ACNE Yaz Plusis indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no knowncontraindications to oral contraceptive therapy and have achieved menarche.Yaz Plusshould be used for the treatment ofacne only if the patient desires an oral contraceptive for birth control. 1.4 FOLATE SUPPLEMENTATION Yaz Plusis indicatedin women who choose to use an oral contraceptive as their method of contraception,to raisefolatelevels for the purpose of reducing the risk of a neural t Læs hele dokumentet